Evidence map›Paper›PMID 25168239›Full record

ArticleCell death and differentiation2015

Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking.

B Martin-Antonio, A Najjar, S N Robinson, C Chew, S Li, E Yvon, M W Thomas, I Mc Niece, R Orlowski, C Muñoz-Pinedo and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Natural Killer Cells: Angels and Devils for Immunotherapy.International journal of molecular sciences · 2017
    Review
  10. Article
  11. Review
  12. Targeted Therapies in Adult B-Cell Malignancies.BioMed research international · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

B Martin-Antonio1] Department of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA [2] Department of Hematology, Hospital Clinic, IDIBAPS, Josep Carreras Leukaemia Research Institute/University of Barcelona, Barcelona, Spain.
A NajjarDepartment of Cancer Systems Imaging, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
S N RobinsonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
C ChewDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
S LiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
E YvonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
M W ThomasDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
I Mc NieceDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
R OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
C Muñoz-PinedoCell Death Regulation Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
C BuenoJosep Carreras Leukemia Research Institute and Cell Therapy Program of the School of Medicine, University of Barcelona, Barcelona, Spain.
P Menendez1] Josep Carreras Leukemia Research Institute and Cell Therapy Program of the School of Medicine, University of Barcelona, Barcelona, Spain [2] Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
C Fernández de LarreaDepartment of Hematology, Hospital Clinic, IDIBAPS, Josep Carreras Leukaemia Research Institute/University of Barcelona, Barcelona, Spain.
A Urbano-IspizuaDepartment of Hematology, Hospital Clinic, IDIBAPS, Josep Carreras Leukaemia Research Institute/University of Barcelona, Barcelona, Spain.
E J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
N ShahDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texs M.D. Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USJosep Carreras Leukaemia Research Institute · ESUniversitat de Barcelona · ESInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
PR1-specific CB T cells for Patients with Myeloid MalignanciesP01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KAUR, INDRESHPAL · 2011 to 2022
$24.4M
NCI NIH HHS P01 CA148600
6 · The paper itself

Abstract

Natural killer cells (NK) are important effectors of anti-tumor immunity, activated either by the downregulation of HLA-I molecules on tumor cells and/or the interaction of NK-activating receptors with ligands that are overexpressed on target cells upon tumor transformation (including NKG2D and NKP30). NK kill target cells by the vesicular delivery of cytolytic molecules such as Granzyme-B and Granulysin activating different cell death pathways, which can be Caspase-3 dependent or Caspase-3 independent. Multiple myeloma (MM) remains an incurable neoplastic plasma-cell disorder. However, we previously reported the encouraging observation that cord blood-derived NK (CB-NK), a new source of NK, showed anti-tumor activity in an in vivo murine model of MM and confirmed a correlation between high levels of NKG2D expression by MM cells and increased efficacy of CB-NK in reducing tumor burden. We aimed to characterize the mechanism of CB-NK-mediated cytotoxicity against MM cells. We show a Caspase-3- and Granzyme-B-independent cell death, and we reveal a mechanism of transmissible cell death between cells, which involves lipid-protein vesicle transfer from CB-NK to MM cells. These vesicles are secondarily transferred from recipient MM cells to neighboring MM cells amplifying the initial CB-NK cytotoxicity achieved. This indirect cytotoxicity involves the transfer of NKG2D and NKP30 and leads to lysosomal cell death and decreased levels of reactive oxygen species in MM cells. These findings suggest a novel and unique mechanism of CB-NK cytotoxicity against MM cells and highlight the importance of lipids and lipid transfer in this process. Further, these data provide a rationale for the development of CB-NK-based cellular therapies in the treatment of MM.

Indexed as

Immunity, CellularCaspase 3FemaleFetal BloodGranzymesHumansK562 CellsKiller Cells, NaturalMaleMultiple MyelomaNatural Cytotoxicity Triggering Receptor 3NK Cell Lectin-Like Receptor Subfamily KReactive Oxygen SpeciesSecretory VesiclesCASP3 protein, humanCaspase 3GranzymesGZMB protein, humanKLRK1 protein, humanNatural Cytotoxicity Triggering Receptor 3NCR3 protein, humanNK Cell Lectin-Like Receptor Subfamily KReactive Oxygen Species

Identifiers

PMID25168239
PMCPMC4262774
OpenAlexW2092303252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.